Hydrocortisone acetate suppositories are indicated for use in inflamed hemorrhoids, post–irradiation (factitial) proctitis, as an adjunct in the treatment of chronic ulcerative colitis, cryptitis, other inflammatory conditions of the anorectum, and pruritus ani.
One suppository in the rectum morning and night for two weeks, in nonspecific proctitis. In more severe cases, one suppository three times daily; or two suppositories twice daily. In factitial proctitis, recommended therapy is six to eight weeks or less, according to the response of the individual case. All prescription substitutions and/or recommendations using this product shall be made subject to state and fede...
www.fda.gov/medwatchEach Rectal Suppository contains 25 mg hydrocortisone acetate in a hydrogenated vegetable oil base.
Hydrocortisone acetate is a corticosteroid. Chemically, hydrocortisone acetate is pregn–4–ene–3, 20–dione, 21–(acetyloxy)–11, 17–dihydroxy (11ß)– with the following structural formula:
In normal subjects, about 26 percent of hydrocortisone acetate is absorbed when the hydrocortisone acetate suppository is applied to the rectum. Absorption of hydrocortisone acetate may vary across abraded or inflamed surfaces. Topical steroids are primarily effective because of their anti–inflammatory, anti–pruritic and vasoconstrictive action.
Hydrocortisone acetate suppositories are indicated for use in inflamed hemorrhoids, post–irradiation (factitial) proctitis, as an adjunct in the treatment of chronic ulcerative colitis, cryptitis, other inflammatory conditions of the anorectum, and pruritus ani.
Hydrocortisone suppositories are contraindicated in those patients with a history of hypersensitivity to any of the components.
1. Do not use unless adequate proctologic examination is made.
2. If irritation develops, the product should be discontinued and appropriate therapy instituted.
3. In the presence of an infection, the use of an appropriate antifungal or antibacterial agent should be instituted. If a favorable response does not occur promptly, the corticosteroid should be discontinued until the infection has been adequately controlled.
No long–term studies in animals have been performed to evaluate the carcinogenic potential of corticosteroid suppositories.
Staining of fabric may occur with use of the suppository. Precautionary measures are recommended.
In laboratory animals, topical steroids have been associated with an increase in the incidence of fetal abnormalities when gestating females have been exposed to rather low dosage levels. There are no adequate and well–controlled studies in pregnant women.
Hydrocortisone suppositories should only be used during pregnancy if the potential benefit justifies the risk to the fetus. Drugs of this class should not be used extensively on pregnant patients, in large amounts, or for prolonged periods of time.
It is not known whether this drug is excreted in human milk, and because many drugs are excreted in human milk and because of the potential for serious adverse reactions in nursing infants from hydrocortisone suppositories, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.
The following local adverse reactions have been reported with hydrocortisone suppositories: Burning, itching, irritation, dryness, folliculitis, hypopigmentation, allergy contact dermatitis, secondary infection.
To report suspected adverse reactions, contact Vitruvias Therapeutics at 1–844–451–5944 or FDA @ 1–800–FDA–1088 or www.fda.gov/medwatch.
Drug abuse and dependence has not been reported in patients treated with hydrocortisone acetate suppositories.
If signs and symptoms of systemic overdosage occur, discontinue use.
One suppository in the rectum morning and night for two weeks, in nonspecific proctitis. In more severe cases, one suppository three times daily; or two suppositories twice daily. In factitial proctitis, recommended therapy is six to eight weeks or less, according to the response of the individual case.
All prescription substitutions and/or recommendations using this product shall be made subject to state and federal statutes as applicable. Please NOTE: This is not an Orange Book product and has not been subjected to FDA therapeutic or other equivalency testing. No representation is made as to generic status or bioequivalency. Each person recommending a prescription substitution using this product shall make such recommendation based on his/her professional knowledge and opinion, upon evaluating the active ingredients, inactive ingredients, excipients and chemical information provided herein.
Hydrocortisone acetate 25 mg Suppositories are off–white, cylinder shaped, with one end tapered. Package of 12 suppositories (NDC 69680–144–12) and package of 24 suppositories (NDC 69680–144–24).
Store at 20°-25°C (68°-77°F). See USP Controlled Temperature. Store away from heat. Protect from freezing.
Rx only.
Avoid excessive handling of the suppository. It is designed to melt at body temperature.
1. Separate plastic film at top opening and pull downward.
2. Continue pulling downward to almost the full length of the suppository.
3. Gently remove the suppository from the film pocket.
Manufactured by:
Graxcell Pharmaceutical, LLC.
136 Oak Drive
Syosset , NY 11791
Manufactured for:
Vitruvias Therapeutics
Auburn, AL 36830
I144 0321R0
Revised 03/2021
NDC 69680-144-12
VITRUVIAS
therapeutics
Hydrocortisone Acetate
Suppositories 25 mg
Rx only
12 Suppositories
| Package NDC | Billing unit | Product NDC | DailyMed indexing SPL | SPL version | Effective |
|---|---|---|---|---|---|
| 69680-144-12 | EA - Each | 69680-144 | 39fe8b94-aaca-40f1-baf2-cce6e711cbda | 1 | 2021-09-07 |
| 69680-144-24 | EA - Each | 69680-144 | af55208c-6f82-44c6-9a13-d74dcc2c78c2 | 1 | 2021-09-07 |
Every source-derived product name is available through these pages.
| Product NDC | Package NDC |
|---|---|
| 69680-144 | 69680-144-12, 69680-144-24 |
Every source-derived ingredient row is available through these pages.
| Name | UNII | Kind |
|---|---|---|
| HYDROCORTISONE ACETATE | 3X7931PO74 | ACTIB |
| HYDROGENATED COCO-GLYCERIDES | XDD37N2GPR | IACT |
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| d38b4993-22b9-49e2-b004-52f4504310fe | 290de58f-fb3f-4120-aea7-4561cdf60fee | 2024-12-30 | Adverse reactions | 290de58f-fb3f-4120-aea7-4561cdf60fee |
Adverse event summaries are temporarily unavailable. Other product information remains available.